Roth Capital Increases Earnings Estimates for ChromaDex

ChromaDex Co. (NASDAQ:CDXC) – Roth Capital upped their FY2025 earnings estimates for ChromaDex in a research note issued to investors on Wednesday, March 5th. Roth Capital analyst S. Mcgowan now anticipates that the company will earn $0.07 per share for the year, up from their previous forecast of $0.05. The consensus estimate for ChromaDex’s current full-year earnings is $0.04 per share. Roth Capital also issued estimates for ChromaDex’s Q4 2025 earnings at $0.03 EPS, Q1 2026 earnings at $0.01 EPS, Q2 2026 earnings at $0.02 EPS, Q3 2026 earnings at $0.04 EPS, Q4 2026 earnings at $0.06 EPS and FY2027 earnings at $0.27 EPS.

Several other research analysts have also recently weighed in on CDXC. Roth Mkm upped their price objective on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. LADENBURG THALM/SH SH boosted their price objective on shares of ChromaDex from $6.80 to $8.10 and gave the stock a “buy” rating in a research report on Wednesday. Finally, StockNews.com raised shares of ChromaDex from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 24th.

ChromaDex Stock Up 52.7 %

Shares of NASDAQ CDXC opened at $8.55 on Thursday. ChromaDex has a twelve month low of $1.57 and a twelve month high of $9.18. The company’s fifty day moving average is $5.68 and its 200-day moving average is $5.13. The stock has a market cap of $653.07 million, a price-to-earnings ratio of 855.86 and a beta of 2.21.

Institutional Investors Weigh In On ChromaDex

Several hedge funds have recently bought and sold shares of CDXC. USA Financial Formulas bought a new stake in shares of ChromaDex during the 4th quarter valued at $25,000. State of Wyoming bought a new stake in ChromaDex during the fourth quarter valued at $39,000. Mercer Global Advisors Inc. ADV acquired a new stake in ChromaDex in the 4th quarter valued at $53,000. Truist Financial Corp acquired a new stake in shares of ChromaDex in the 4th quarter worth about $54,000. Finally, FMR LLC bought a new position in ChromaDex during the 3rd quarter valued at $55,000. 15.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the sale, the director now directly owns 244,179 shares of the company’s stock, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 9.64% of the stock is owned by corporate insiders.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.